Cinoxacin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317534

CAS#: 28657-80-9

Description: Cinoxacin was an older synthetic antimicrobial related to the quinolone class of antibiotics with activity similar to oxolinic acid and nalidixic acid. It was commonly used thirty years ago to treat urinary tract infections in adults. There are reports that cinoxacin had also been used to treat initial and recurrent urinary tract infections and bacterial prostatitis in dogs however this veterinary use was never approved by the FDA. In complicated UTI, the older gyrase-inhibitors such as cinoxacin are no longer indicated.

Chemical Structure

img
Cinoxacin
CAS# 28657-80-9
Instruction

Theoretical Analysis

MedKoo Cat#: 317534
Name: Cinoxacin
CAS#: 28657-80-9
Chemical Formula: C12H10N2O5
Exact Mass: 262.06
Molecular Weight: 262.220
Elemental Analysis: C, 54.97; H, 3.84; N, 10.68; O, 30.51

Price and Availability

Size Price Availability Quantity
50mg USD 150
100mg USD 250
250mg USD 450
Bulk inquiry

Synonym: Cinoxacin; Cinobac; Compound 64716; Cinoxacine; Cinoxacino; Cinoxacinum;Acid, Azolinic; Azolinic Acid;

IUPAC/Chemical Name: 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid

InChi Key: VDUWPHTZYNWKRN-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)

SMILES Code: CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 262.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Quercia O, Rafanelli S, Emiliani F, Stefanini GF. Anaphylactic reaction to
cinoxacin: report of one case associated with inferior acute myocardial
infarction. Eur Ann Allergy Clin Immunol. 2003 Feb;35(2):61-3. PubMed PMID:
12674041.


2: López-Gresa MP, Ortiz R, Perelló L, Latorre J, Liu-González M, García-Granda
S, Pérez-Priede M, Cantón E. Interactions of metal ions with two quinolone
antimicrobial agents (cinoxacin and ciprofloxacin). Spectroscopic and X-ray
structural characterization. Antibacterial studies. J Inorg Biochem. 2002 Sep
30;92(1):65-74. PubMed PMID: 12230989.


3: Parshikov IA, Moody JD, Heinze TM, Freeman JP, Williams AJ, Sutherland JB.
Transformation of cinoxacin by Beauveria bassiana. FEMS Microbiol Lett. 2002 Aug
27;214(1):133-6. PubMed PMID: 12204384.


4: Sesia G, Cauda F, Alladio F. [Comparison of efficacy and tolerability among 3
quinolones in the treatment of lower urinary tract infections (cinoxacin versus
ciprofloxacin and pefloxacin]. Minerva Urol Nefrol. 1992 Jul-Sep;44(3):217-8.
Italian. PubMed PMID: 1492275.


5: Cristiano P, Morelli G, Simioli F, Iovene MR, Della Vittoria Scarpati M,
Manguso L. [Comparative evaluation of norfloxacin and cinoxacin in the therapy of
complicated infections of the urinary tract]. Minerva Med. 1989 Apr;80(4):393-5.
Italian. PubMed PMID: 2657499.


6: Izumi T, Nagayama T, Kitagawa T. Protein binding of quinolonecarboxylic acids.
II. Spectral changes on the interaction of cinoxacin, nalidixic acid and
pipemidic acid with human and rat albumins. Chem Pharm Bull (Tokyo). 1989
Mar;37(3):746-52. PubMed PMID: 2752488.


7: Pino A, Maura A, Grillo P. Absence of cinoxacin-induced DNA fragmentation and
mutations in the rat granuloma pouch. Environ Mol Mutagen. 1989;13(2):112-5.
PubMed PMID: 2917551.


8: Bardi M, Manzoni A. [Treatment of postoperative urinary infections in
obstetrics and gynecology with cinoxacin]. Clin Ter. 1988 Nov 15;127(3):185-8.
Italian. PubMed PMID: 2976355.


9: Pfau A, Sacks TG, Shapiro M. Prevention of recurrent urinary tract infections
in premenopausal women by post-coital administration of cinoxacin. J Urol. 1988
Jun;139(6):1250-2. PubMed PMID: 3286892.


10: Seppänen J. Cinoxacin vs trimethoprim--safety and efficacy in the prophylaxis
of uncomplicated urinary tract infections. Drugs Exp Clin Res.
1988;14(10):669-71. PubMed PMID: 3246212.


11: Hayashi Y, Terao E, Yamasaki I. [Study of clinical efficacy and safety of
long-term cinoxacin therapy of chronic urogenital organ infection]. Hinyokika
Kiyo. 1987 May;33(5):799-805. Japanese. PubMed PMID: 3661347.


12: Goldstein EJ, Kahn RM, Alpert ML, Ginsberg BP, Greenway FL, Citron DM.
Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A
randomized, double-blind trial. Am J Med. 1987 Apr 27;82(4A):284-7. PubMed PMID:
3555049.


13: Aimè G, Governa M, Polledro P. [Comparative evaluation of cinoxacin,
cotrimoxazole and pipemidic acid in recurrent infections of the lower urinary
tract in long-term therapy]. Minerva Urol Nefrol. 1987 Apr-Jun;39(2):129-34.
Italian. PubMed PMID: 3498226.


14: Pennisi M, Viscusi G, Salanitri G, Cammarata E, Gazzo G. [Comparative
clinical study of the antibacterial activity of cinoxacin and norfloxacin in
urinary tract infections]. Minerva Urol Nefrol. 1987 Jan-Mar;39(1):51-6. Italian.
PubMed PMID: 3616862.


15: Digranes A, Dibb WL, Benonisen E. In vitro activities of ciprofloxacin,
ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim.
Chemotherapy. 1985;31(6):466-71. PubMed PMID: 2934234.


16: Martorana G, Giberti C, Damonte P. [Preventive treatment of recurrent
cystitis in women. Double-blind randomized study using cinoxacin and placebo].
Minerva Urol Nefrol. 1984 Jan-Mar;36(1):43-9. Italian. PubMed PMID: 6398519.


17: Burt RA. Review of adverse reactions associated with cinoxacin and other
drugs used to treat urinary tract infections. Urology. 1984 Jan;23(1):101-7.
PubMed PMID: 6362163.


18: Heessen FW, Muytjens HL. In vitro activities of ciprofloxacin, norfloxacin,
pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
Antimicrob Agents Chemother. 1984 Jan;25(1):123-4. PubMed PMID: 6230988; PubMed
Central PMCID: PMC185448.


19: Brogard JM, Comte F, Lavillaureix J. Comparative pharmacokinetic profiles of
cinoxacin and pipemidic acid in humans. Eur J Drug Metab Pharmacokinet. 1983
Jul-Sep;8(3):251-9. PubMed PMID: 6653617.


20: Vuye A. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and
oxolinic acid. Arzneimittelforschung. 1983;33(12):1623-7. PubMed PMID: 6230083.